Stryker Corporation (SYK)

Stryker reported better-than-expected revenue in Q1 2025, with sales up 11.9% year-on-year to $5.87 billion, and adjusted EPS of $2.84. Despite this, Stryker decreased its full-year adjusted EPS forecast due to new import taxes, while simultaneously increasing its full-year sales growth guidance. The stock reached its 52-week high on January 27, 2025. As of July 22, 2025, the stock has shown a 3.32% rise over the last month and a 16.18% increase over the last year. Insider selling activity was observed in May 2025, and institutional investors showed mixed activity in Q1 2025. Stryker completed the acquisition of Inari Medical in January 2025 and the divestiture of its U.S. spinal implants business in April 2025. Stryker is scheduled to release its Q2 2025 financial results on July 31, 2025.

While specific seasonal patterns are not detailed, Stryker's business is influenced by factors that can lead to fluctuations. Demand for certain products can be affected by external events such as pandemics. Generally, the demand for medical devices and technologies is poised to rise due to evolving healthcare systems, an aging population, and an increasing number of operations. Unpredictable increases in demand have, at times, exceeded the company's capacity to meet them timely, which could affect customer relationships and lead to negative publicity.

Stryker Corporation is a global medical technology company that designs, manufactures, and markets a diverse range of medical equipment and devices, operating primarily within the Healthcare sector. Its business is segmented into MedSurg and Neurotechnology, and Orthopaedics. Stryker offers orthopedic implants, surgical equipment and navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, neurotechnology products, and other medical devices.

Stryker has a significant global presence, selling products in approximately 75 countries through subsidiaries, branches, and third-party distributors. The U.S. market accounts for over 70% of sales in 2023, but Stryker is focused on globalization and sees international growth opportunities, particularly in emerging markets. In 2024, approximately 27% of Stryker's net sales were generated outside the United States.

Stryker maintains a strong brand reputation, recognized for its quality and innovation. The company has been listed among Forbes' "Most Trusted Companies in America" and "Best Employers" in 2025 and honored as a "Great Place to Work" and among the "World's Best Workplaces" in 2024. Positive events include showcasing advancements in Mako SmartRobotics™ at the AAOS 2025 Annual Meeting, receiving FDA clearance for new products, continuing partnerships to support brain tumor research and initiatives like Project C.U.R.E., and releasing its 2024 Comprehensive Report. No specific negative events significantly impacting Stryker's brand reputation in the past year were found.

Stryker Corporation's ownership is primarily held by institutional shareholders and insiders. Institutional shareholders own approximately 77.55% of the company, while Stryker insiders own about 90.45%. Retail investors hold a smaller portion, approximately 0.00% according to one source, though another indicates around 54.76% is owned by public companies and individual investors. Key individual owners include Jon L. Stryker, Ronda E. Stryker, and Pat Stryker. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Greenleaf Trust, State Street Corp, JPMorgan Chase & Co, and Price T Rowe Associates Inc /md/.